Literature DB >> 18519816

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.

Alessandro M Vannucchi1, Elisabetta Antonioli, Paola Guglielmelli, Alessandro Pancrazzi, Vittoria Guerini, Giovanni Barosi, Marco Ruggeri, Giorgina Specchia, Francesco Lo-Coco, Federica Delaini, Laura Villani, Silvia Finotto, Emanuele Ammatuna, Renato Alterini, Valentina Carrai, Gloria Capaccioli, Simonetta Di Lollo, Vincenzo Liso, Alessandro Rambaldi, Alberto Bosi, Tiziano Barbui.   

Abstract

Among 994 patients with essential thrombocythemia (ET) who were genotyped for the MPLW515L/K mutation, 30 patients carrying the mutation were identified (3.0%), 8 of whom also displayed the JAK2V671F mutation. MPLW515L/K patients presented lower hemoglobin levels and higher platelet counts than did wild type (wt) MPL; these differences were highly significant compared with MPLwt/JAK2V617F-positive patients. Reduced hemoglobin and increased platelet levels were preferentially associated with the W515L and W515K alleles, respectively. MPL mutation was a significant risk factor for microvessel disturbances, suggesting platelet hyperreactivity associated with constitutively active MPL; arterial thromboses were increased only in comparison to MPLwt/JAK2wt patients. MPLW515L/K patients presented reduced total and erythroid bone marrow cellularity, whereas the numbers of megakaryocytes, megakaryocytic clusters, and small-sized megakaryocytes were all significantly increased. These data indicate that MPLW515L/K mutations do not define a distinct phenotype in ET, although some differences depended on the JAK2V617F mutational status of the counterpart.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18519816     DOI: 10.1182/blood-2008-01-135897

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  66 in total

Review 1.  Do we know more about essential thrombocythemia because of JAK2V617F?

Authors:  Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

Review 2.  What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Authors:  Paola Guglielmelli; Giada Rotunno; Annalisa Pacilli; Alessandro Maria Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

3.  Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.

Authors:  Julia Asp; Björn Andréasson; Ulrika Hansson; Carina Wasslavik; Johanna Abelsson; Peter Johansson; Lars Palmqvist
Journal:  Haematologica       Date:  2016-01-14       Impact factor: 9.941

4.  Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.

Authors:  Hadrian Szpurka; Anna M Jankowska; Hideki Makishima; Juraj Bodo; Nelli Bejanyan; Eric D Hsi; Mikkael A Sekeres; Jaroslaw P Maciejewski
Journal:  Leuk Res       Date:  2010-03-23       Impact factor: 3.156

Review 5.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes; Srdan Verstovsek
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

Review 6.  JAK2 inhibitors: what's the true therapeutic potential?

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Blood Rev       Date:  2010-11-20       Impact factor: 8.250

7.  Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.

Authors:  Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Dietrich Beelen; Peter Bojko; Dieter Bürkle; Robert Dengler; Andrea Distelrath; Michael Eckart; Robert Eckert; Stefan Fries; Jan Knoblich; Georg Köchling; Hans-Peter Laubenstein; Petro Petrides; Manfred Planker; Rudolf Pihusch; Rudolf Weide; Wolfgang Kern; Torsten Haferlach
Journal:  Haematologica       Date:  2008-11-23       Impact factor: 9.941

8.  JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Authors:  Paola Guglielmelli; Giovanni Barosi; Lisa Pieri; Elisabetta Antonioli; Alberto Bosi; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2008-11-27       Impact factor: 9.941

9.  A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.

Authors:  Alessandro Pancrazzi; Paola Guglielmelli; Vanessa Ponziani; Gaetano Bergamaschi; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi
Journal:  J Mol Diagn       Date:  2008-07-31       Impact factor: 5.568

10.  Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

Authors:  Mohamad Bassam Sonbol; Belal Firwana; Ahmad Zarzour; Mohammad Morad; Vishal Rana; Ramon V Tiu
Journal:  Ther Adv Hematol       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.